Literature DB >> 14664706

Threshold effects of glucose transporter-4 (GLUT4) deficiency on cardiac glucose uptake and development of hypertrophy.

S J Kaczmarczyk1, S Andrikopoulos, J Favaloro, A A Domenighetti, A Dunn, M Ernst, D Grail, M Fodero-Tavoletti, C E Huggins, L M Delbridge, J D Zajac, J Proietto.   

Abstract

The aim of this study was to investigate the metabolic and structural consequences of a decrease in glucose transporter-4 (GLUT4) levels on the heart. The CreLoxP system was utilised to delete GLUT4 in muscle tIssue including heart. The presence of the PGK-neoR cassette in the GLUT4-Lox mice resulted in reduced expression in all tIssues to levels 15-30% of wild-type control mice. In mice expressing Cre recombinase, there was a further reduction of GLUT4 in cardiac tIssue to almost undetectable levels. Cardiac glucose uptake was measured basally and during a euglycaemic/hyperinsulinaemic clamp using 2-deoxy-[1-(14)C]glucose. Insulin-stimulated glucose uptake was normal in hearts expressing 15% of normal GLUT4 levels but markedly reduced in mice with more profound reduction in GLUT4. Cardiac enlargement occurred only when GLUT4 levels were less than 5% of normal values. In heart there is a threshold level of GLUT4 above which insulin-stimulated glucose uptake is maintained. As little as 5% of normal GLUT4 levels expressed in heart is sufficient to prevent the development of cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14664706     DOI: 10.1677/jme.0.0310449

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  14 in total

1.  Subclinical impairment of left ventricular function in diabetic patients with or without obesity: A study based on three-dimensional speckle tracking echocardiography.

Authors:  Q Wang; Y Gao; K Tan; P Li
Journal:  Herz       Date:  2014-12-11       Impact factor: 1.443

2.  Chronic AICAR treatment prevents metabolic changes in cardiomyocytes exposed to free fatty acids.

Authors:  Christelle Viglino; Bernard Foglia; Christophe Montessuit
Journal:  Pflugers Arch       Date:  2019-05-31       Impact factor: 3.657

3.  Development of GLUT4-selective antagonists for multiple myeloma therapy.

Authors:  Changyong Wei; Richa Bajpai; Horrick Sharma; Monique Heitmeier; Atul D Jain; Shannon M Matulis; Ajay K Nooka; Rama K Mishra; Paul W Hruz; Gary E Schiltz; Mala Shanmugam
Journal:  Eur J Med Chem       Date:  2017-08-14       Impact factor: 6.514

Review 4.  Energy substrate metabolism in cardiac hypertrophy.

Authors:  Michael F Allard
Journal:  Curr Hypertens Rep       Date:  2004-12       Impact factor: 5.369

Review 5.  Knockout mouse models of insulin signaling: Relevance past and future.

Authors:  Anne E Bunner; P Charukeshi Chandrasekera; Neal D Barnard
Journal:  World J Diabetes       Date:  2014-04-15

Review 6.  Insulin Signaling and Heart Failure.

Authors:  Christian Riehle; E Dale Abel
Journal:  Circ Res       Date:  2016-04-01       Impact factor: 17.367

Review 7.  Role of monosaccharide transport proteins in carbohydrate assimilation, distribution, metabolism, and homeostasis.

Authors:  Anthony J Cura; Anthony Carruthers
Journal:  Compr Physiol       Date:  2012-04       Impact factor: 9.090

8.  Maternal Hyperglycemia Directly and Rapidly Induces Cardiac Septal Overgrowth in Fetal Rats.

Authors:  Erin E Gordon; Benjamin E Reinking; Shanming Hu; Jianrong Yao; Kok L Kua; Areej K Younes; Chunlin Wang; Jeffrey L Segar; Andrew W Norris
Journal:  J Diabetes Res       Date:  2015-05-07       Impact factor: 4.011

9.  Lost in translation.

Authors:  David H Wasserman; Julio E Ayala; Owen P McGuinness
Journal:  Diabetes       Date:  2009-09       Impact factor: 9.461

10.  Emerging role for antioxidant therapy in protection against diabetic cardiac complications: experimental and clinical evidence for utilization of classic and new antioxidants.

Authors:  Michael F Hill
Journal:  Curr Cardiol Rev       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.